Abstract. Childhood Hodgkin lymphoma is one of the most curable pediatric malignancies, with long-term overall survival now approaching 90%–98% in modern cooperative-group series. Because cure is achieved in the great majority of patients, the central question in contemporary management is no longer whether children can be cured, but how they can be cured with the lowest possible burden of late toxicity. Combination therapy has therefore evolved from broad-field radiotherapy plus intensive chemotherapy toward risk-adapted, response-based multiagent regimens in which chemotherapy intensity, use of radiotherapy, and more recently incorporation of targeted agents are tailored according to stage, tumor bulk, B symptoms, and early treatment response. This review analyzes the results of combination treatment in childhood Hodgkin lymphoma with emphasis on major pediatric trials, including P9425, AHOD0031, GPOH-HD-2002, EuroNet-PHL-C1, AHOD0831, and AHOD1331. A narrative review methodology was used to identify landmark studies, late-effect cohorts, and contemporary reviews relevant to combined-modality therapy in children and adolescents. The published evidence shows that multiagent chemotherapy remains the therapeutic backbone, while radiotherapy can be safely omitted in selected patients with favorable early response. At the same time, targeted augmentation of chemotherapy with brentuximab vedotin has improved outcomes in high-risk disease without a clear increase in acute toxicity. The major challenge remains balancing event-free survival with long-term risks such as infertility, cardiotoxicity, pulmonary damage, and second malignant neoplasms. Current data support a modern paradigm of biologically and clinically individualized combination therapy, in which disease control and survivorship are considered equally important endpoints [1-17].